Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Free Cash Flow for 3 consecutive years, with -$14.7 million as the latest value for Q4 2025.

  • For Q4 2025, Free Cash Flow changed 0.33% year-over-year to -$14.7 million; the TTM value through Dec 2025 reached -$77.1 million, down 38.47%, while the annual FY2025 figure was -$77.1 million, 38.47% down from the prior year.
  • Free Cash Flow hit -$14.7 million in Q4 2025 for Artiva Biotherapeutics, up from -$19.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$10.9 million in Q3 2023 and bottomed at -$22.4 million in Q2 2025.
  • Average Free Cash Flow over 3 years is -$15.5 million, with a median of -$14.7 million recorded in 2024.
  • On a YoY basis, Free Cash Flow climbed as much as 0.33% in 2025 and fell as far as 63.45% in 2025.
  • Artiva Biotherapeutics' Free Cash Flow stood at -$11.3 million in 2023, then crashed by 30.09% to -$14.7 million in 2024, then rose by 0.33% to -$14.7 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$14.7 million, -$19.3 million, and -$22.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.